ResultsIQ

ResultsIQ › Latest results › Vimta Labs Limited

Vimta Labs Limited Q2 FY26 earnings call summary

NSE: VIMTALABS · BSE: 524394

Earnings call of 3 Nov 2025, summarised by AI from the filing.

Vimta Labs Q2 FY26 revenue ₹1,045 million, up 22.3% year-on-year, with biologics commercialization targeted for Q1 FY27.

Key takeaways

  1. Q2 revenue ₹1,045 million (Q2 FY25: ₹854 million, up 22.3% year-on-year), highest ever quarterly revenue.
  2. Biologics timeline Biologics facility ready by end of Q3 FY26, commercialization by Q1 FY27.
  3. Growth driver Pharma research and testing and food testing services are major contributors to revenue growth.

Original filing on BSE

Vimta Labs Limited Q1 FY27 results

As filed: Revenue ₹109 cr (+11% year on year), EBITDA ₹37.3 cr (+13% year on year), PAT ₹21.0 cr (+11% year on year), EBITDA margin 34.2% (+54 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹109 cr (+16% year on year), EBITDA ₹39.4 cr (+23% year on year), PAT ₹21.1 cr (+17% year on year), EBITDA margin 36.0% (+199 bps). Score 50 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 199 bps year on year. Share price after the results: +6.6% in 30 days (Nifty 500: −2.9%).
  • Q3 FY26: Revenue ₹98.6 cr (+11% year on year), EBITDA ₹34.2 cr (+4% year on year), PAT ₹17.6 cr (−16% year on year), EBITDA margin 34.7% (−236 bps). Score 35 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 236 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹9.6 cr on a year ago, more than the ₹9.0 cr it added the year before. Share price after the results: −15.3% in 30 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹102 cr (+23% year on year), EBITDA ₹33.0 cr (+18% year on year), PAT ₹20.0 cr (+33% year on year), EBITDA margin 32.4% (−138 bps). Score 52 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 138 bps year on year. Revenue rose ₹19.0 cr on a year ago, more than the ₹11.0 cr it added the year before. Share price after the results: −7.4% in 30 days (Nifty 500: +0.6%).
  • Q1 FY26: Revenue ₹98.0 cr (+23% year on year), EBITDA ₹33.0 cr (+43% year on year), PAT ₹19.0 cr (+58% year on year), EBITDA margin 33.7% (+492 bps). Score 66 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was in line with it. EBITDA margin rose 492 bps year on year. Share price after the results: +39.4% in 28 days (Nifty 500: −3.4%).
  • Q4 FY25: Revenue ₹94.0 cr (+21% year on year), EBITDA ₹32.0 cr (+28% year on year), PAT ₹18.0 cr (+50% year on year), EBITDA margin 34.0% (+199 bps). Score 65 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 199 bps year on year. Profit fell 14% from last quarter. Share price after the results: −4.5% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹90.0 cr (+10% year on year), EBITDA ₹34.0 cr (+48% year on year), PAT ₹22.0 cr (+120% year on year), EBITDA margin 37.8% (+973 bps). Score 70 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well above it. EBITDA margin rose 973 bps year on year.
  • Q2 FY25: Revenue ₹85.0 cr (+16% year on year), EBITDA ₹29.0 cr (+81% year on year), PAT ₹15.0 cr (+150% year on year), EBITDA margin 34.1% (+1,000 bps). Score 87 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Vimta Labs Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.